Previous 10 | Next 10 |
2023-08-13 05:30:32 ET Summary PDS Biotechnology Corporation has had a volatile stock performance in recent years. The company has made slow and steady progress advancing its pipeline and is well-liked within the analyst firm community. With two registrational studies on the h...
PRINCETON, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating plat...
PRINCETON, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating plat...
Data from ongoing VERSATILE-002 trial to highlight HPV16-specific T cell responses in subjects receiving PDS0101 and KEYTRUDA ® for recurrent or metastatic HPV16-positive head and neck cancer FLORHAM PARK, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nas...
FLORHAM PARK, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune ® ...
Composition of matter and use patent for Versamune ® in combination with PDS0301 allowed in Canada PDS Biotech’s proprietary combination of Versamune ® based PDS0101 and PDS0301 with an immune checkpoint inhibitor resulted in 21 months median overall survival in a...
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corp. (NASDAQ: PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today its expected addition to the broad-market Russell 2000 ® ...
2023-06-14 09:12:07 ET PDS Biotechnology Corporation ( NASDAQ: PDSB ) announced Wednesday that Stage two of its Phase 2 trial for its lead asset PDS0101 in head and neck cancer reached the efficacy threshold with Merck’s ( NYSE: MRK ) anti-PD-1 therapy, Keytruda. ...
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed objective response Efficacy and safety continue to be monitored as additional patients have ye...
2023-06-06 09:49:10 ET Following a ~31% decline in the previous session, the shares of PDS Biotechnology ( NASDAQ: PDSB ) rose ~9% in the pre-market Tuesday as Cantor Fitzgerald and H.C. Wainwright defended the stock arguing that the selloff was overdone. H.C. Wainwright analyst...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...
Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15,...